Drug Profile
CTL 119
Alternative Names: Anti-CD19 CAR-T cell therapy - Novartis/University of Pennsylvania; CTL119; huCART19; huCTL019Latest Information Update: 09 Mar 2023
Price :
$50
*
At a glance
- Originator University of Pennsylvania
- Developer Novartis; University of Pennsylvania
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Precursor cell lymphoblastic leukaemia-lymphoma
- Phase I Lymphoid leukaemia; Non-Hodgkin's lymphoma
- No development reported B-cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia; Multiple myeloma
Most Recent Events
- 10 Jan 2023 University of Pennsylvania plans a phase I/II trial for Precursor cell lymphoblastic leukaemia-lymphoma (In infants, In children, In adolescents, In adults, Combination therapy) by January 2023 (Parenteral) (NCT05674175)
- 10 Dec 2022 Safety and efficacy data from a phase I trial in Non-Hodgkin's lymphoma and Lymphoid leukaemia presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-2022)
- 28 Dec 2021 No recent reports of development identified for clinical-Phase-Unknown development in Precursor-cell-lymphoblastic-leukaemia-lymphoma(Combination therapy, In children, Second-line therapy or greater) in USA (IV, Infusion)